Écouen, France, January 14, 2020 – Vygon Group, a specialist single-use medical devices group, today announces the appointment of Peter Ciriello as its USA CEO, effective from January 1, 2020. He will be based out of the Vygon US headquarters in Lansdale (PA) and will also oversee activities at the Dover (NH) facility.
Ciriello brings a wealth of experience and knowledge to the Vygon team. He is a strategic global senior executive with a wide range of leadership expertise and proven success in increasing business value, developing strong customer and supplier relationships, operations management, engineering and technology, along with new product and business development.
Peter previously worked as a managing partner for Clearwater Organic Farms where he was also one of its founders. Prior to this he held posts as executive vice president of Cinram International, was CEO of Carthuplas, Inc. and president and CEO of Advanced Duplication Systems.
Ciriello joined Vygon in November 2018 and quickly became a key member of the US leadership team. He takes over from Les Davies, CEO, Vygon UK and vice president for the UK/North America region, who assumed the role for two years in addition to his other responsibilities.
“Appointing a full-time Vygon USA CEO is a clear reflection of the current needs of the business and our confidence in Peter’s ability to lead the future growth and success of this subsidiary. We congratulate Peter on his promotion and look forward to working together to increase our market share in this area,” said Stéphane Regnault, CEO of Vygon Group. “The organization and board of directors would also like to thank Les Davies for his accomplishments during his tenure as US CEO.”
Vygon USA employs 138 staff at its facilities in Lansdale (PA) and Dover (NH). Key strategic focuses include improving standards and practices to help reduce venous depletion for all patients, keeping babies safe in the NICUs with enteral feeding and the golden hour products, and continuing the education of pharmacists on the new USP 800 compounding standards.
With medical expenses that can reach approximately $10,422 p.a. per person in the United States in 2020, opportunities for Vygon continue to grow.
Vygon USA has several new products planned for launch in 2020 that are complementary to the current product groups. Ciriello is looking to further enhance alignment with the Vygon France business units in key medical market areas in an effort to leverage worldwide R&D and marketing capabilities.
About Vygon Group
Vygon designs, manufactures and markets high-tech single-use medical devices for healthcare professionals in hospital and for private and independent practitioners. Vygon is a world leader within this industry, offering a wide range of products in a number of clinical specialties. Organized in five business units (Intensive Care – Obstetrics Neonatology Enteral – Intravascular Therapies – Cardiovascular & Surgery – Anesthesia & Emergency), Vygon combines local and international in-depth expertise and know-how in each individual field. With expertise right along the value chain, from product design to the delivery of training for medical personnel, Vygon provides health care professionals with effective and innovative products tailored to their needs and those of their patients, for optimum use and safety.
The company distributes over 205 million products a year in more than 120 countries through its network of 26 subsidiaries and 331 distributors. Vygon products display the CE and/or FDA mark and are manufactured in the group’s eight factories in Europe, the USA and Colombia.
A family company founded in 1962, Vygon is based in Ecouen, in France’s Greater Paris region. It is a mid-sized business employing 2,350 staff worldwide. The turnover in 2018 was €323 million ($360M), with 81% of this derived from Vygon’s international business.